Clinical Trials

Every treatment that has ever made a difference in cancer care was once a part of a clinical trial. MUSC Hollings Cancer Center is committed to offering the best treatments available today while searching for even better ones for the future. Ask your doctor if a clinical trial is right for you.

Protocol Title Status Contact
103475 A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer OPEN TO ACCRUAL Contact
103370 A Multi-Center Phase Ib Trial Evaluating the Safety and Efficacy of Lacutamab in Patients With Relapse Peripheral T-Cell Lymphoma That Express KIR3DL2 OPEN TO ACCRUAL Contact
103388 Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation OPEN TO ACCRUAL Contact
103013 A Phase II Study of Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma OPEN TO ACCRUAL Contact
103341 First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGF; Fusion Protein BCA101 Alone and in Combination with Pembrolizumab in Patients with EGFR-Driven Advanced Solid Tumors OPEN TO ACCRUAL Contact
103382 Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Select Rare CNS Cancers OPEN TO ACCRUAL Contact
103419 Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial OPEN TO ACCRUAL Contact
103397 A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features OPEN TO ACCRUAL Contact
103337 Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT) OPEN TO ACCRUAL Contact
103266 Phase 3 Study of Loncastuximab Tesirine, an Anti-CD-19 Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) OPEN TO ACCRUAL Contact
103385 Phase I Trial With Expansion Cohort of DNA-PK Inhibition and IMRT in Cisplatin-Ineligible Patients With Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) OPEN TO ACCRUAL Contact
103411 Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study OPEN TO ACCRUAL Contact
103299 Pivotal, Randomized, Open-Label Study of Optune® (Tumor Treating Fields, 200kHz) Concomitant With Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma OPEN TO ACCRUAL Contact
103260 A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma OPEN TO ACCRUAL Contact
103417 The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib OPEN TO ACCRUAL Contact
103448 A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY) OPEN TO ACCRUAL Contact
103258 Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects OPEN TO ACCRUAL Contact
103309 A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Subjects With Myelofibrosis OPEN TO ACCRUAL Contact
103288 An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors (IGNYTE) OPEN TO ACCRUAL Contact
103366 Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) OPEN TO ACCRUAL Contact